The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study
Tóm tắt
Most of hepatocellular carcinoma (HCC) arises on the background of chronic inflammation. The presence of infiltrating inflammatory cells is associated with tumour initiation, progression and clinical response to treatment. The influence of white blood cell (WBC) subtype counts on HCC progression remains unclear. In this study, we performed a Mendelian randomization (MR) study with the validation of two datasets. The summary data for WBC counts were extracted from a recent large GWAS of individuals of European ancestry. The GWAS data related to HCC were obtained from the UK Biobank (UKB). Univariable and multivariable MR analyses were used to identify risk factors genetically associated with HCC risks. In the discovery dataset, multivariable MR analysis revealed that sum basophil neutrophil counts had an independent causal effect on the occurrence of HCC, with the sum basophil neutrophil counts as follows: (OR = 0.437, P = 0.003, CI 0.252–0.757). Similarly, in the validation dataset, total basophil neutrophil counts were also been identified as an independent risk factor for HCC. The sum basophil neutrophil counts were as follows: (OR = 0.574, P = 0.021, CI 0.358–0.920). In the European population, genetically predicted lower total basophil neutrophil counts might be an independent risk factor for HCC.
Từ khóa
Tài liệu tham khảo
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. https://doi.org/10.1038/nrdp.2016.18.
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001.
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.
Chen Y, Liao Y, Lam LM, et al. Pretreatment biomarkers as prognostic predictors of survival in patients with pancreatic cancer treated with gemcitabine-based therapy and 5-fluorouracil: neutrophil-to-lymphocyte ratio vs platelet-to-lymphocyte ratio. Int J Med Sci. 2020;17(10):1449–57. https://doi.org/10.7150/ijms.46254.
Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272(2):342–51. https://doi.org/10.1097/SLA.0000000000003239.
Dharmapuri S, Ozbek U, Lin JY, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med. 2020;9(14):4962–70. https://doi.org/10.1002/cam4.3135.
Margetts J, Ogle LF, Chan SL, et al. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118(2):248–57. https://doi.org/10.1038/bjc.2017.386.
Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer. 2020;20(1):937. https://doi.org/10.1186/s12885-020-07105-8.
Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2022;19(4):257–73. https://doi.org/10.1038/s41575-021-00568-5.
Guo L, Ren H, Pu L, Zhu X, Liu Y, Ma X. The prognostic value of inflammation factors in hepatocellular carcinoma patients with hepatic artery interventional treatments: a retrospective study. Cancer Manag Res. 2020;12:7173–88. https://doi.org/10.2147/CMAR.S257934.
Kong W, Xu H, Cheng J, et al. The prognostic role of a combined fibrinogen and neutrophil-to-lymphocyte ratio score in patients with resectable hepatocellular carcinoma: a retrospective study. Med Sci Monit. 2020;26:e918824. https://doi.org/10.12659/MSM.918824.
Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8. https://doi.org/10.1002/bjs.10123.
Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663–73. https://doi.org/10.1007/s00330-020-06931-5.
Davies NM, Holmes MV, Davey SG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. https://doi.org/10.1136/bmj.k601.
Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–63. https://doi.org/10.1002/sim.3034.
Kanai M, Akiyama M, Takahashi A, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. Nat Genet. 2018;50(3):390–400. https://doi.org/10.1038/s41588-018-0047-6.
Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. 2016;167(5):1415–29. https://doi.org/10.1016/j.cell.2016.10.042.
Reiner AP, Lettre G, Nalls MA, et al. Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). PLoS Genet. 2011;7(6):e1002108. https://doi.org/10.1371/journal.pgen.1002108.
Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616–21. https://doi.org/10.1038/s41588-021-00954-4.
Kruger P, Saffarzadeh M, Weber AN, et al. Neutrophils: between host defence, immune modulation, and tissue injury. PLoS Pathog. 2015;11(3):e1004651. https://doi.org/10.1371/journal.ppat.1004651.
Kalafati L, Kourtzelis I, Schulte-Schrepping J, et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-85 e12. https://doi.org/10.1016/j.cell.2020.09.058.
Gershkovitz M, Caspi Y, Fainsod-Levi T, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res. 2018;78(10):2680–90. https://doi.org/10.1158/0008-5472.CAN-17-3614.
Rice CM, Davies LC, Subleski JJ, et al. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat Commun. 2018;9(1):5099. https://doi.org/10.1038/s41467-018-07505-2.
He X, Cao Y, Gu Y, et al. Clinical outcomes and immune metrics in intratumoral basophil-enriched gastric cancer patients. Ann Surg Oncol. 2021;28(11):6439–50. https://doi.org/10.1245/s10434-021-09815-0.
Wang C, Chen YG, Gao JL, et al. Low local blood perfusion, high white blood cell and high platelet count are associated with primary tumor growth and lung metastasis in a 4T1 mouse breast cancer metastasis model. Oncol Lett. 2015;10(2):754–60. https://doi.org/10.3892/ol.2015.3304.
Bax HJ, Chauhan J, Stavraka C, et al. Basophils from cancer patients respond to immune stimuli and predict clinical outcome. Cells. 2020. https://doi.org/10.3390/cells9071631.
Isaacson NH, Rapoport P. Eosinophilia in malignant tumors; its significance. Ann Intern Med. 1946;25(6):893–902. https://doi.org/10.7326/0003-4819-25-6-893.
Li F, Du X, Lan F, et al. Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abb5943.
Wang Z, Chen B, Fu Y, et al. Eosinophilia and lung cancer: analysis from real-world data and Mendelian randomization study. Front Med (Lausanne). 2022;9:830754. https://doi.org/10.3389/fmed.2022.830754.
Kung IT, Chan SK, Fung KH. Fine-needle aspiration in hepatocellular carcinoma combined cytologic and histologic approach. Cancer. 1991;67(3):673–80. https://doi.org/10.1002/1097-0142(19910201)67:3%3c673::aid-cncr2820670324%3e3.0.co;2-h.
Kwak HS, Han YM, Lee JM. Focal eosinophilic infiltration of the liver mimicking hepatocellular carcinoma: case reports. Clin Imaging. 2004;28(1):36–9. https://doi.org/10.1016/s0899-7071(03)00098-6.
Watanabe T, Aikawa K, Kanefuji T, et al. Pelioid-type hepatocellular carcinoma with numerous eosinophilic infiltrations in a patient with primary biliary cirrhosis. Hepatol Res. 2008;38(4):421–7. https://doi.org/10.1111/j.1872-034X.2007.00277.x.
Fu Q, Chen N, Ge C, et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019;8(7):1593806. https://doi.org/10.1080/2162402X.2019.1593806.
Zhang D, He W, Wu C, et al. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. 2019;10:71. https://doi.org/10.3389/fimmu.2019.00071.
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22. https://doi.org/10.1038/ni.2703.
Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery. 2006;139(6):755–64. https://doi.org/10.1016/j.surg.2005.10.009.